However, HER-4 positive immunostaining in >10% of the tumour cells was associated with a better disease-free survival (53.43 ± 6.50 vs. 36.0 ± 4.3 months, p = 0.042) in these patients (Figure 2B). The gene discussed is ERBB4; the disease is neoplasm.